explore -WSS

explore

author：knowledge 2025-09-27 16:50:14 - browse：59

Anna Yeo/STAT

Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way.

Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

Previous article： Cancer drug shortages should be causing more outrage
Next article： FDA approves Moderna’s RSV vaccine, its second licensed product

WSS

FDA investigates CAR

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

The EPA's new lead rule: How one expert crunched the numbers

Takeda, Janssen join wearable maker to measure scratching

The most pressing bird flu mysteries scientists want answered

knowledge

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

An outdated Medicare rule harms dementia patients with anxiety

Anesthesiologist group: stop taking Ozempic before surgery

ReNAgade cuts staff seven months after raising $300 million

United colonoscopy coverage change 'may cost lives,' doctors say

FTC loses bid to block Novant's North Carolina hospital merger

ChatGPT in medicine: STAT answers readers' burning questions

Structure Therapeutics oral GLP

Moonlake's readout produced a cash windfall. Risks remain

Despite FDA concern, risk that CAR

hotspot

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

What to do when lifesaving products contribute to climate change

What don’t we know about an Alzheimer’s drug side effect?

Fetal surgery at risk from Dobbs and new abortion restrictions

Sutter Health’s antitrust win overturned by appeals court

Sutter Health’s antitrust win overturned by appeals court

hotspot

focus

focus

leisure time